Empowering patients through education: Moderna and XO Life partner to advance digital education on RSV and vaccination

Munich, Germany, 17th November, 2025 — Moderna Germany GmbH, leader in the creation of the field of mRNA medicine, and XO Life, an innovative digital health scale-up, have announced a strategic collaboration in the area of digital vaccine education to advance RSV vaccination through digital patient support.

As part of this partnership, XO Life’s brite™ platform will feature a dedicated section on RSV (Respiratory syncytial Virus) and RSV vaccination — offering a structured, digital patient journey enriched with medically verified content. The initiative aims to improve patient awareness, foster vaccine confidence, and facilitate access to key information about RSV and the importance of vaccination. Content will be available across web, iOS, and Android applications. 

"At Moderna, our ambition goes far beyond mRNA innovation — we are committed to ensuring that science translates into real-world impact. That means improving access, supporting healthcare professionals, and helping build a more efficient and resilient healthcare system. Vaccination should not be seen as a burden, but as an act of protection — a long-term investment in the health of our society. I’m truly excited about our partnership with XO Life and their brite™ platform. Together, we are empowering patients with accessible, personalized information that supports informed decisions and strengthens confidence in vaccination — especially at a time when prevention has never been more critical in Germany."
— Andreas Pollner, General Manager, Moderna Germany

Dr. Friderike Bruchmann, Co-Founder & CEO of XO Life, adds: "Patient education starts with clear, accessible information that addresses people’s individual needs. Our user-friendly brite™ platform promotes access to such information exactly where patients need it – in everyday life, on their smartphones, and in an engaging format." 

Following free registration, users will have 24/7 access to clear, medically reviewed information. Additionally, they will be able to document their vaccination appointments and history, and, if needed, seek expert advice. The brite™ platform also enables users to connect with others, fostering motivation and emotional support. With its wide range of features, the platform ensures that users always have important vaccination information at hand, can track their vaccination journey, and receive quick, understandable answers to open questions.

‍

brite™ Platform: empowering patients through digital education on RSV and vaccination

As RSV continues to place a significant burden on older adults in Germany—accounting for over 12,800 hospitalizations and more than 1,340 deaths annually in the season 2022-2023—there is a clear need to strengthen prevention through better education.

brite™ platform. Through on-demand guidance, peer interaction, and digital self-tracking, the initiative supports a more informed and proactive patient experience. It strengthens health literacy, fosters confidence in preventive care — including vaccination — and contributes to a more efficient and resilient healthcare system.

‍

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. 

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit: https://www.modernatx.com/de-DE

About XO Life

XO Life has developed brite™, a globally unique meta-platform for digitally supporting patients during product use and therapy. Patients are accompanied throughout their treatment journey with medically verified, health-related content, can track their health and therapy progress, receive personalized insights, expert medical support, and connect with other patients. 

Manufacturers can license their own product- and therapy-specific areas on the brite™ platform, providing patients with customized branding, content, questions, and services. Through personalized information and continuous support throughout the course of therapy, manufacturers make a valuable contribution to treatment success, adherence, and patient safety. 

XO Life is considered one of the most promising players in the German and European healthcare sector and is among the leading digital health scale-ups. The company is a market leader in Germany and collaborates with global market leaders, the German pharmaceutical mid-size sector, as well as orphan drug manufacturers. Most recently, the brite™ platform has been made available globally in multiple languages.

More links

Website: www.xo-life.com

LinkedIn: https://www.linkedin.com/company/xo-life

YouTube: https://www.youtube.com/@xo-life/featured

‍

Press contact

XO Life GmbH

Dr. med. Lisa M. Köhler

Head of Medical Affairs & Pharmacovigilance

Agnes-Pockels-Bogen 1  

80992 München

Email: pr@xo-life.com

‍

Moderna

Clothilde Caillet

Director, Country and Europe Communications Lead

Email: Clothilde.caillet@modernatx.com